The thing that gives me some comfort that the markets understand...

The thing that gives me some comfort that the markets understand this risk, Phaedrus, of the company not being able to come up with the goods for full or accelerated paediatric approval ie. without having an actual successful adult trial having been done, is in its current share price. Short term success in the comparability study or studies is simply not priced in. I don’t think the FDA allowed itself to say anything about the suitability of potency 1b in the Type A meeting, even though we have been guided by the company to think that it’ s an enhanced, matrix version. At least the suspense in the next couple of months is not as bad as it would have been without the rights issue, simply because the number of near term risks is down to the failure to produce further data to connect the clinical trial product with the commercial inventory.